Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 10/31/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: September 1, 2018 - September 30, 2018

 

MOR - 3

Balance Sheet

(Unaudited)

 

     Orexigen Therapeutics, Inc.  

$ USD ‘000s

   As of March 11, 2018      As of September 30, 2018  

Assets

     

Current assets:

     

Cash and cash equivalents

   $ 21,372      $ 33,457  

Accounts receivable, net

     19,203        —    

Inventory

     8,857        —    

Prepaid expenses and other current assets

     6,868        7,095  

Intercompany receivable(1)

     93,353        —    
  

 

 

    

 

 

 

Total current assets

     149,653        40,552  

Non-current assets:

     

Property and equipment, net

     543        —    

Investment in Subsidiary(1)

     19,000        —    

Intangible assets

     66,566        —    

Other long-term assets

     588        1,252  

Restricted cash

     100        110  
  

 

 

    

 

 

 

Total assets

   $ 236,450      $ 41,914  
  

 

 

    

 

 

 

Liabilities and Stockholders’ Equity

     

Current liabilities:

     

Accounts payable (2)

     925        1,374  

DIP loan

     —          —    

Accrued expenses

     3,921        6,265  
  

 

 

    

 

 

 

Total current liabilities:

     4,846        7,639  
  

 

 

    

 

 

 

Total liabilities not subject to compromise

     4,846        7,639  

Total liabilities subject to compromise

     110,381        243,277  

Series Z preferred stock

     3,343        —    

Stockholders’ equity (deficit)

     117,880        (209,002
  

 

 

    

 

 

 

Total liabilities and stockholders’ equity (deficit)

   $ 236,450      $ 41,914  
  

 

 

    

 

 

 

Notes:

 

(1)

Investment in Subsidiary $19m reclassed from Intercompany Receivable at March 11, 2018 to properly align for reporting.

(2)

Accounts payable excludes all liabilities assumed by the purchaser under the terms of the Asset Purchase Agreement.